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ABSTRACT
Objectives The efﬁcacy of tocilizumab (TCZ), an anti-
interleukin-6 receptor antibody, has not previously been
evaluated in a population consisting exclusively of
patients with early rheumatoid arthritis (RA).
Methods In a double-blind randomised controlled trial
(FUNCTION), 1162 methotrexate (MTX)-naive patients
with early progressive RA were randomly assigned
(1:1:1:1) to one of four treatment groups: 4 mg/kg TCZ
+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo and
placebo+MTX (comparator group). The primary outcome
was remission according to Disease Activity Score using
28 joints (DAS28–erythrocyte sedimentation rate (ESR)
<2.6) at week 24. Radiographic and physical function
outcomes were also evaluated. We report results through
week 52.
Results The intent-to-treat population included 1157
patients. Signiﬁcantly more patients receiving 8 mg/kg
TCZ+MTX and 8 mg/kg TCZ+placebo than receiving
placebo+MTX achieved DAS28-ESR remission at week
24 (45% and 39% vs 15%; p<0.0001). The 8 mg/kg
TCZ+MTX group also achieved signiﬁcantly greater
improvement in radiographic disease progression and
physical function at week 52 than did patients treated
with placebo+MTX (mean change from baseline in van
der Heijde–modiﬁed total Sharp score, 0.08 vs 1.14
(p=0.0001); mean reduction in Health Assessment
Disability Index, −0.81 vs −0.64 (p=0.0024)). In
addition, the 8 mg/kg TCZ+placebo and 4 mg/kg TCZ
+MTX groups demonstrated clinical efﬁcacy that was at
least as effective as MTX for these key secondary
endpoints. Serious adverse events were similar among
treatment groups. Adverse events resulting in premature
withdrawal occurred in 20% of patients in the 8 mg/kg
TCZ+MTX group.
Conclusions TCZ is effective in combination with MTX
and as monotherapy for the treatment of patients with
early RA.
Trial registration number ClinicalTrials.gov, number
NCT01007435
INTRODUCTION
Patients with rheumatoid arthritis (RA) can achieve
long-term beneﬁcial clinical and radiographic out-
comes with early, effective treatment.1–3 For those
with severe RA and poor prognostic features (sero-
positivity, erosive disease, high disease activity),
recommendations support early intensive treatment
to achieve remission or low disease activity,4 5
thus maximising long-term beneﬁts. This may
include use of conventional disease-modifying
antirheumatic drugs (DMARDs) in combination or
early initiation of a biological DMARD.
Interleukin-6 (IL-6) plays a pivotal role in RA
pathogenesis, and has been implicated in the
development of systemic symptoms and local
inﬂammation, pannus formation and bone resorp-
tion leading to joint damage.6 7 RA disease activity
correlates with elevated IL-6 level and activity.7 8
Tocilizumab (TCZ), a humanised monoclonal
antibody that binds to IL-6 receptor-α and inhibits
IL-6–mediated pro-inﬂammatory signalling,9 has
demonstrated efﬁcacy and safety in the treatment of
patients with RA.10–14 Four phase III trials have
demonstrated the clinical beneﬁt of combining TCZ
with DMARDs in patients with RA with inadequate
responses to DMARDs (including antitumour
necrosis factor (anti-TNF) agents).10 12–14 Three
trials have demonstrated the efﬁcacy and safety of
TCZ monotherapy in patients with RA.11 15 16
The efﬁcacy of inhibiting IL-6 signalling has not
been evaluated previously in a population consisting
exclusively of methotrexate (MTX)-naive patients
with early RA. We present results from the primary
analysis of the ﬁrst 52 weeks of FUNCTION, a
2-year phase III trial evaluating clinical and radio-
graphic efﬁcacy and safety of TCZ, in combination
with MTX and as monotherapy, in early RA.
METHODS
Trial design
FUNCTION was a multicentre, double-blind,
double-dummy, parallel-group, phase III trial in
which patients were randomly assigned (1:1:1:1) to
4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/
kg TCZ+placebo or placebo+MTX. The random-
isation sequence was stratiﬁed by serological status
(presence of rheumatoid factor (RF) and/or anticyc-
lic citrullinated peptide (anti-CCP) antibodies) and
by geographical region. TCZ or placebo was admi-
nistered intravenously every 4 weeks. MTX/placebo
was initiated at 7.5 mg/week (to accommodate local
recommendations of some countries at the time of
study design), and was increased to a maximum of
20 mg/week by week 8 in patients with ongoing
swollen or tender joints.
The trial was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed
consent.
Patients
Adults (≥18 years) with moderate to severe active
RA, classiﬁed according to revised 1987 American
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College of Rheumatology (ACR) criteria,17 of ≤2 years’ dur-
ation who had not previously received MTX or biological
agents were included. Patients with features of poor prognosis
were enrolled: inclusion criteria included Disease Activity Score
using 28 joints and erythrocyte sedimentation rate (DAS28-ESR)
>3.2, swollen joint count ≥4 (66 joint count), tender joint
count ≥6 (68 joint count), ESR ≥28 mm/h or C reactive protein
≥1 mg/dl, positive RF or anti-CCP antibodies or one or more
erosion of hands, wrists or feet attributable to RA based on a
central radiographic reading. Before baseline, DMARDs were
withdrawn for appropriate washout periods (see online
supplementary appendix). Patients could continue treatment
with oral non-steroidal anti-inﬂammatory drugs and/or oral cor-
ticosteroids (≤10 mg/day prednisone or equivalent), provided
the doses had been stable for at least 2 or 4 weeks before base-
line, respectively, and remained stable throughout the study.
Patients could withdraw from the study at any time for any
reason. In addition, withdrawal was recommended for patients
who had alanine aminotransferase (ALT) or aspartate amino-
transferase (AST) elevations ≥3× the upper limit of normal
(ULN) that was accompanied by total bilirubin >2× ULN;
withdrawal was required for patients with ALTor ASTelevations
>5× ULN.
Endpoints
The proportion of patients achieving remission (DAS28-ESR
<2.6) at week 24 was the primary endpoint. Key secondary
endpoints included assessment of ACR response criteria, radio-
graphic efﬁcacy by the van der Heijde–modiﬁed total Sharp
score (mTSS), quality of life using the Short Form-36 (SF-36)
physical and mental component scores (PCS and MCS) and
physical function assessment by the Health Assessment
Questionnaire–Disability Index (HAQ-DI) score. Exploratory/
post hoc analyses included evaluation of Clinical Disease
Activity Index (CDAI <2.8) remission and ACR/European
League Against Rheumatism (EULAR) preliminary criteria for
remission. Serum levels of TCZ were measured. Safety was
evaluated by the frequency and severity of adverse events (AEs).
Statistical analysis
Analysis of efﬁcacy was performed on the intent-to-treat popula-
tion (all randomly assigned patients who received at least one
TCZ/placebo infusion). The safety population included all
patients who received at least one TCZ/placebo infusion and
had at least one post-dose safety assessment.
Overall, the study required 1128 patients (282 per arm) to
provide 80% power to detect an absolute difference of 10% in
DAS28-ESR remission (DAS28-ESR <2.6) rate in the primary
comparison between 8 mg/kg TCZ+MTX and placebo+MTX
(assumed DAS28 remission rates were 26% and 16%, respect-
ively, under the null hypothesis of no treatment difference) in a
two-sided test with a 5% signiﬁcance level. The study was not
powered to detect differences between TCZ groups. The sample
size was not inﬂated to account for withdrawals as the primary
analysis implemented a non-responder imputation approach that
accounted for withdrawals.
Primary and all secondary efﬁcacy endpoints were evaluated
sequentially in a ﬁxed hierarchy of statistical testing (with priori-
tisation of the primary comparator group, 8 mg/kg TCZ
+MTX) to reduce the occurrence of false-positive conclusions
resulting from multiple testing (see online supplementary
appendix table S1). For the primary endpoint and dichotomous
response variables (eg, ACR responses), TCZ groups were com-
pared with the placebo+MTX group using logistic regression,
adjusted for stratiﬁcation factors (serological status and region)
within the model. Patients who withdrew or for whom a
DAS28-ESR score or an ACR20/50/70 response could not be
determined were considered non-responders.
Changes from baseline in radiographic scores at week 52
were compared between the TCZ and placebo+MTX groups
using non-parametric Van Elteren analysis stratiﬁed by region
and serological status using linear extrapolation for missing
data. Other continuous variables (eg, HAQ-DI score) were
analysed using analysis of covariance that included treatment
group, baseline score and baseline stratiﬁcation factors.
Non-radiographic continuous endpoints used a combination
of last-observation-carried-forward and no imputation for
missing data.
RESULTS
Patient population
In total, 1162 patients were randomly assigned, and 920 (79%)
completed 52 weeks of treatment; 96.1% of patients assigned to
4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX or placebo+MTX
achieved MTX doses of 15 mg/week or higher (see online
supplementary appendix, results and tables S2–S4). Although
overall withdrawal rates were similar among groups (ﬁgure 1),
withdrawals in the placebo+MTX group were driven primarily
by non-safety–related reasons (most notably insufﬁcient thera-
peutic response and treatment refusal); withdrawals in the TCZ
groups were driven primarily by safety (AEs, most notably
laboratory abnormalities), with the highest incidence in the
8 mg/kg TCZ+MTX group, in which 47 of 291 patients
(16.2%) experienced an AE that led to withdrawal (see Safety).
Baseline demographics and disease characteristics were
balanced among treatment groups (table 1). Overall, patients
had very early RA (mean duration, 0.4–0.5 years) with little
radiographic damage at baseline (mean mTSS score, 5.66–7.72).
Most patients were also RF or anti-CCP antibody positive
(89%–91% and 86%–87%, respectively).
Efﬁcacy
Signs and symptoms
The primary endpoint was met: statistically signiﬁcantly more
patients achieved DAS28-ESR remission at weeks 24 and 52
with 8 mg/kg TCZ+MTX than with placebo+MTX (45% vs
15% and 49% vs 20%, respectively; p<0.0001; table 2; OR,
24-week analysis, 4.77; p<0.0001). Signiﬁcantly more 8 mg/kg
TCZ+placebo than placebo+MTX patients achieved
DAS28-ESR remission at week 24 (39% vs 15%; p<0.0001).
Results from sensitivity analyses were consistent with those of
the primary analysis (see online supplementary appendix, results
and table S5). Mean DAS28-ESR scores decreased over time to
week 52 in all groups; the 8 mg/kg TCZ+MTX group consist-
ently showed the greatest decrease from baseline (ﬁgure 2A) and
the lowest mean scores.
Signiﬁcantly greater response rates were also observed for
8 mg/kg TCZ+MTX versus placebo+MTX for ACR20/50/70
responses at weeks 24 and 52 (p≤0.0142; ﬁgure 2B,C).
DAS28-ESR remission and ACR response rates indicated
improvement in RA signs and symptoms in the 8 mg/kg TCZ
+placebo and 4 mg/kg TCZ+MTX groups at weeks 24 and 52
(table 2, ﬁgure 2B, C). A non-signiﬁcant result in the statistical
testing hierarchy (see online supplementary appendix table S1)
occurred at the comparison of week 24 ACR50 response
between 8 mg/kg TCZ+placebo and placebo+MTX
(p=0.2743). Therefore, all endpoints subsequently tested in the
hierarchical chain were considered non-signiﬁcant.
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Improvements in SF-36 PCS and MCS were observed in all
arms at weeks 24 and 52; the numerically greatest changes were
with 8 mg/kg TCZ+MTX (see online supplementary appendix
ﬁgure S1). Analysis of ACR/EULAR Boolean and Index remis-
sion and CDAI remission demonstrated numerically higher
remission rates with 8 mg/kg TCZ+MTX than with placebo
+MTX at week 24; however, as exploratory endpoints, these
were not adjusted for multiplicity (ﬁgure 2B).
Radiographic
Compared with placebo+MTX, inhibition of joint damage was
signiﬁcantly greater with 8 mg/kg TCZ+MTX (mean (SD)
change in mTSS=0.08 (2.09) vs 1.14 (4.30); p=0.0001; ﬁgure
3A). Mean changes from baseline to week 52 in mTSS were
smaller with 8 mg/kg TCZ+placebo and 4 mg/kg TCZ+MTX
(mean (SD), 0.26 (1.88) and 0.42 (2.93), respectively) than with
placebo+MTX (1.14 (4.30); ﬁgure 3A). Up to 83% of patients
in all TCZ-treated groups showed no radiographic progression
from baseline (change in mTSS ≤0) at weeks 24 and 52, whereas
73% in the placebo+MTX group showed no change (see online
supplementary appendix ﬁgure S2). Mean change from baseline
to week 52 in erosion and joint space narrowing scores followed
a trend similar to that of the overall mTSS (ﬁgure 3A).
Sensitivity analyses conﬁrmed these ﬁndings (see online
supplementary appendix ﬁgure S3). The cumulative distribution
plot of change from baseline in mTSS at week 52 shows a shift
to the right, indicating less progression of joint damage for the
TCZ groups than for the placebo+MTX group (ﬁgure 3B).
Physical function
Signiﬁcantly greater improvements in mean HAQ-DI scores
from baseline to week 52 were observed for 8 mg/kg TCZ
+MTX than for placebo+MTX (mean, −0.81 vs −0.64; differ-
ence (95% CI) from placebo+MTX, −0.17 (−0.28 to −0.06),
p=0.0024; ﬁgure 2D). Both 8 mg/kg TCZ+placebo and 4 mg/
kg TCZ+MTX showed improvements in HAQ-DI scores from
baseline to week 52 (mean (difference from placebo+MTX;
95% CI), −0.67 (−0.03 to −0.15; 0.08) and −0.75 (−0.11 to
−0.22; 0.00), respectively) at least equal to those of placebo
+MTX (−0.64).
Serum levels
In patients for whom data were available, after the administra-
tion of study drug, serum concentration proﬁles of TCZ were
similar with 8 mg/kg TCZ+placebo and 8 mg/kg TCZ+MTX
and lower with 4 mg/kg TCZ+MTX (ﬁgure 4).
Safety
AEs/serious AEs (SAEs) were reported in 88.3%/10.7% of 8 mg/
kg TCZ+MTX patients, 85.6%/8.6% of 8 mg/kg TCZ+placebo
patients, 88.6%/10.0% of 4 mg/kg TCZ+MTX patients and
83.3%/8.5% of placebo+MTX patients (table 3). AEs resulting
in premature withdrawal occurred in 20.3% of 8 mg/kg TCZ
+MTX patients, 11.6% of 8 mg/kg TCZ+placebo patients,
12.1% of 4 mg/kg TCZ+MTX patients and 7.4% of placebo
+MTX patients. In all TCZ treatment groups, the most
common reasons for treatment discontinuation were attributed
Figure 1 Patient disposition. *Five patients (two in the placebo+MTX group, two in the 4 mg/kg TCZ+MTX group and one in the 8 mg/kg TCZ
+MTX group) did not receive study treatment and were excluded from analysis populations. Withdrawals in the placebo+MTX group were mainly
driven by insufﬁcient therapeutic response and refused treatment; withdrawals in the TCZ combination therapy groups were mainly related to safety
(primarily hepatic transaminase elevations). Two patients randomly assigned to the placebo+MTX group received TCZ at the baseline visit and were
allocated to the 4 mg/kg TCZ+MTX group for safety analysis. The ITT population comprised 1157 patients, and the safety population comprised
1153 patients. ITT, intent-to-treat; MTX, methotrexate; TCZ, tocilizumab.
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to the investigations system organ class, particularly events
related to liver enzyme elevations (the most common preferred
terms in TCZ groups were ALT increased (27 patients), trans-
aminase increased (22 patients) and AST increased (4 patients)).
The most frequently reported AEs and SAEs were infections;
the percentage of infections was similar overall in the two 8
mg/kg TCZ groups and the placebo+MTX group and a numer-
ically higher percentage of infections in the 4 mg/kg TCZ
Table 1 Baseline demographics and disease characteristics (ITT population)
Placebo+MTX
n=287
4 mg/kg TCZ+MTX
n=288
8 mg/kg TCZ+MTX
n=290
8 mg/kg TCZ +placebo
n=292
Missing values
(all groups), n
Female, n (%) 229 (80) 228 (79) 228 (79) 219 (75) 0
Age, years 49.6±13.10 (50.0) 51.2±13.84 (53.0) 49.5±13.70 (50.5) 49.9±13.22 (51.0) 0
Duration of RA, years 0.4±0.48 (0.2) 0.4±0.49 (0.2) 0.5±0.53 (0.3) 0.5±0.48 (0.2) 0
DMARD naive, n (%)* 228/282 (80.9) 236/289 (81.7) 230/290 (79.3) 223/292 (76.4) 4
Number of previous DMARDs† 0.2±0.41 (0.0) 0.2±0.41 (0.0) 0.2±0.49 (0.0) 0.3±0.52 (0.0) 0
0, n (%) 228 (80.9) 236 (81.7) 230 (79.3) 223 (76.4) –
1, n (%) 53 (18.8) 51 (17.6) 53 (18.3) 60 (20.5) –
2, n (%) 1 (0.4) 2 (0.7) 6 (2.1) 8 (2.7) –
3, n (%) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) –
Receiving corticosteroids, n (%) 109 (38) 107 (37) 95 (33) 118 (40) 0
RF positive, n (%) 254 (89) 255 (89) 264 (91) 262‡ (90) 1
Anti-CCP antibody positive, n (%) 246 (86) 245§ (86) 252 (87) 247 (86) 6
DAS28-ESR 6.6±0.99 (6.5) 6.7±1.05 (6.7) 6.7±1.11 (6.8) 6.7±0.99 (6.7) 0
CRP, mg/dL 2.31±2.667 (1.28) 2.59±3.053 (1.58) 2.58±2.978 (1.69) 2.48±3.186 (1.26) 0
ESR, mm/h 50.4±26.81 (44.0) 55.7±30.62 (48.0) 52.8±30.15 (46.0) 51.3±28.39 (41.5) 0
Tender joint count
(68 joints)
27.4±16.54 (23.0) 28.1±15.63 (25.0) 28.7±16.74 (24.5) 28.7±16.33 (25.0) 0
Swollen joint count
(66 joints)
16.2±10.44 (13.0) 16.1±10.16 (13.0) 17.6±12.38 (14.0) 16.5±10.10 (13.0) 0
HAQ-DI score 1.48±0.665 (1.50) 1.62±0.662 (1.75) 1.50±0.625 (1.50) 1.58±0.672 (1.63) 11
Patient pain VAS 59.8±22.02 (62.0) 59.5±22.62 (61.0) 61.6±22.10 (65.0) 62.5±21.82 (65.0) 4
Physician VAS 62.7±17.27 (65.0) 62.4±17.03 (63.0) 63.6±18.12 (65.0) 63.9±18.09 (65.0) 0
Patient global VAS 63.8±21.51 (66.0) 65.3±22.50 (66.0) 66.5±21.46 (70.0) 67.5±22.39 (71.0) 0
mTSS 5.66±14.581 (1.50) 7.72±17.155 (2.00) 6.17±11.078 (2.00) 6.85±16.100 (1.50) 4
JSN score 2.34±7.452 (0.00) 3.60±9.600 (0.00) 2.67±6.488 (0.00) 3.00±8.598 (0.00) 4
Erosion score 3.32±7.642 (1.00) 4.13±8.510 (1.50) 3.49±5.722 (1.50) 3.85±8.299 (1.00) 4
Data are presented as mean±SD (median) unless stated otherwise.
*Reported for the safety population. Note: all patients were MTX naive per protocol.
†Rates of previous DMARD use included for placebo+MTX, 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX and 8 mg/kg TCZ+placebo, respectively, are as follows: hydroxychloroquine, 7%, 4%,
8% and 10%; chloroquine, 4%, 3%, 3% and 4%; sulfasalazine, 6%, 9%, 10% and 9%; leflunomide, 2%, 1%, 1% and 3%; azathioprine, 0%, 0%, 1% and 1%; gold, 0%, <1%, 0% and
<1%; and penicillamine, 0%, 0%, <1% and 0%.
‡Based on 291 patients.
§Based on 286 patients.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; DAS28, Disease Activity Score using 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation
rate; HAQ-DI, Health Assessment Questionnaire–Disability Index; ITT, intent-to-treat; JSN, joint space narrowing; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid
arthritis; RF, rheumatoid factor; TCZ, tocilizumab; VAS, Visual Analogue Scale.
Table 2 Proportions of patients achieving DAS28-ESR remission at week 24 and week 52
Placebo+MTX
n=287
4 mg/kg TCZ+MTX
n=288
8 mg/kg TCZ+MTX
n=290
8 mg/kg TCZ+placebo
n=292
Week 24
Responders, n (%)
(95% CI)
43 (15.0)
(10.9 to 19.1)
92 (31.9)
(26.6 to 37.3)
130 (44.8)
(39.1 to 50.6)
113 (38.7)
(33.1 to 44.3)
p Value vs placebo+MTX <0.0001* <0.0001 <0.0001
OR (95%) relative to placebo+MTX 2.72 (1.80 to 4.11)
p<0.0001*
4.77 (3.19 to 7.14)
p<0.0001
3.70 (2.47 to 5.55)
p<0.0001
Week 52
Responders, n (%)
(95% CI)
56 (19.5)
(14.9 to 24.1)
98 (34.0)
(28.6 to 39.5)
142 (49.0)
(43.2 to 54.7)
115 (39.4)
(33.8 to 45.0)
p Value vs placebo+MTX <0.0001* <0.0001 <0.0001*
ORs were determined by logistic regression analysis.
*The comparison occurred after a break in the hierarchically ordered testing sequence.
DAS28, Disease Activity Score using 28 joints; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TCZ, tocilizumab.
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Figure 2 Efﬁcacy endpoints (A) DAS28-ESR over 52 weeks. Mean DAS28-ESR scores by visit. Error bars show SEM (ITT population). (B) Secondary
and exploratory endpoints at week 24. (C) Secondary and exploratory endpoints at week 52. (D) Change from baseline in HAQ-DI. All
post-withdrawal efﬁcacy data were excluded from analyses. Boolean criteria for ACR/EULAR remission require that the following be satisﬁed at the
same visit: tender joint count (68) ≤1, swollen joint count (66) ≤1, Patient Global Assessment of Disease Activity (cm) ≤1, C-reactive protein
≤1 mg/dL. The index-based deﬁnition of ACR/EULAR remission is an SDAI score ≤3.3. SDAI is deﬁned as the sum of tender joint count (28), swollen
joint count (28), Patient Global Assessment of Disease Activity (cm), Physician Global Assessment of Disease Activity (cm) and C-reactive protein
(mg/dL). ACR endpoints used non-responder imputation; CDAI used LOCF for missing data; ACR/EULAR and HAQ-DI used no imputation for missing
data. ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score using 28 joints; ESR, erythrocyte
sedimentation rate; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire–Disability Index; ITT, intent-to-treat;
LOCF, last-observation-carried-forward; MTX, methotrexate; SDAI, Simpliﬁed Disease Activity Index; TCZ, tocilizumab.
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Figure 2 Continued
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+MTX group (table 3). The most frequently reported serious
infection was pneumonia, accounting for 12 of 35 serious infec-
tions. No opportunistic infections were reported. One newly
diagnosed case of tuberculosis occurred in a patient in the 8 mg/
kg TCZ+MTX group through close exposure to a relative with
active tuberculosis.
Elevations in ALT concentrations according to the Common
Toxicity Criteria (V.3.0; table 3) occurred most frequently in the
TCZ+MTX groups, and were dose dependent: grade ≥2 eleva-
tions were seen in 15.6%, 23.8%, 8.2% and 8.5% of patients in
the 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ
+placebo and placebo+MTX groups, respectively. No instances
of grade 4 elevations were reported. Most elevations >3× the
ULN in all treatment groups occurred at a single time point
during the 52-week treatment period (8.3%, 8.3%, 4.5% and
4.6% with 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/
Figure 3 Inhibition of joint damage over 52 weeks. (A) Mean change in radiographic scores from baseline to week 52 (ITT population). Missing
data were imputed using linear extrapolation. (B) Cumulative probability plot of change in mTSS from baseline based on radiographs taken at
baseline, week 24, week 52 and withdrawal. Radiographic endpoints were analysed using a non-parametric Van Elteren analysis method. Because of
the primary imputation method of linear extrapolation for patients with one baseline and one or more post-baseline radiographs, 93%, 93%, 94%
and 94% of patients in the placebo+MTX group, the 4 mg/kg TCZ+MTX group, the 8 mg/kg TCZ+MTX group and the 8 mg/kg TCZ+placebo
group, respectively, contributed to the week 52 analysis. Linear extrapolation was used for 15% to 17% of patients across all treatment arms at
week 52 (placebo+MTX group, 44/287; 4 mg/kg TCZ+MTX group, 44/288; 8 mg/kg TCZ+MTX group, 50/290; 8 mg/kg TCZ+placebo group, 45/292).
ITT, intent-to-treat; JSN, joint space narrowing; mTSS, van der Heijde–modiﬁed total Sharp score; MTX, methotrexate; TCZ, tocilizumab.
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kg TCZ+placebo and placebo+MTX patients, respectively). No
associations between neutropenia and serious infections or
between thrombocytopenia and bleeding events were observed.
Increases in low-density lipoprotein cholesterol from <160 mg/
dL at baseline to ≥160 mg/dL were reported in 8.0%, 12.1%,
15.1% and 3.2% of 4 mg/kg TCZ+MTX, 8 mg/kg TCZ
+MTX, 8 mg/kg TCZ+placebo and placebo+MTX patients,
respectively.
Thirteen malignancies were reported (ﬁve before day 50);
incidences were similar among all groups. Breast cancer was the
most commonly reported malignancy (three patients; see online
supplementary appendix table S6). Nine deaths occurred: two
in the 8 mg/kg TCZ+MTX group, one in the 8 mg/kg TCZ
+placebo group, four in the 4 mg/kg TCZ+MTX group and
two in the placebo+MTX group. The underlying cause of
death varied across treatment groups (see online supplementary
appendix table S7). Three of four deaths in the 4 mg/kg TCZ
+MTX group were in patients who were older than 80 years.
DISCUSSION
FUNCTION is the ﬁrst trial to examine the effects of inhibiting
IL-6 signalling as a ﬁrst-line therapeutic option for RA. The
study entry criteria speciﬁcally targeted patients with active
disease and features of progressive disease (baseline mean
DAS28-ESR ranged from 6.6 to 6.7; approximately 90% of
enrolled patients were seropositive for RF and/or anti-CCP anti-
bodies), which is the target population for whom early use of
intensive therapy, such as with a biological agent, may be
appropriate.5
Although the study was not powered to detect differences in
treatment effects between the TCZ arms and all doses/regimens
of TCZ demonstrated clinical beneﬁt compared with MTX
alone, the 8 mg/kg TCZ+MTX group consistently achieved the
best outcomes across all efﬁcacy measures. For the duration of
the 52-week study, the 8 mg/kg TCZ+MTX regimen (the
primary comparator) signiﬁcantly improved clinical outcomes
and functional ability (measured by HAQ-DI score) and inhib-
ited joint damage progression compared with the MTX-alone
regimen. The primary endpoint was met: 45% of 8 mg/kg TCZ
+MTX patients achieved DAS28 remission at 24 weeks com-
pared with 15% of placebo+MTX patients. Of interest, in con-
trast to the humanised monoclonal anti-TNF antibody
adalimumab,18 the addition of MTX to TCZ did not result in
TCZ serum levels signiﬁcantly higher than levels attained with
TCZ monotherapy. Although the underlying mechanisms that
drive serum levels of a biological treatment in the context of
combination with MTX versus monotherapy are not fully eluci-
dated, our ﬁndings suggest that synergy between IL-6 inhibition
and MTX action, rather than higher serum drug levels, drives
the higher clinical response observed with TCZ+MTX.
Exploratory analyses across other disease remission measures
(ACR/EULAR Boolean and Index remission, CDAI remission),
which were of clinical importance despite their not being vali-
dated in a clinical trial setting, also showed that improvement
with 8 mg/kg TCZ+MTX was at least equal to improvement
with MTX alone. Analysis of CDAI remission is of particular
interest because this composite disease activity measure does not
include an acute-phase reactant, and it demonstrates that control
Figure 4 Mean serum TCZ concentrations. MTX, methotrexate; TCZ, tocilizumab.
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of disease activity in TCZ-treated patients with early RA was
independent of the direct pharmacodynamic effect of TCZ in
suppressing the synthesis of acute-phase reactant proteins.19
Early radiographic progression contributes to long-term dis-
ability, and prevention of structural joint damage is an important
therapeutic goal early in and throughout the course of the
disease.20 21 Baseline radiographic joint damage was low in all
treatment groups, reﬂecting the early stage of RA in the study
population. This ﬁnding is consistent with other trials in early
RA populations.1 22–24 Throughout 52 weeks, patients treated
with TCZ experienced less radiographic progression than
patients treated with MTX monotherapy, with the greatest joint
damage inhibition in the 8 mg/kg TCZ+MTX group. Of note,
mTSS progression was low overall, even in the comparator
MTX monotherapy arm, as has been observed in other early RA
trials.
The recommended starting dose for intravenous TCZ in the
USA and Canada is 4 mg/kg,25 in contrast to 8 mg/kg used in
the rest of the world; 8 mg/kg TCZ monotherapy has also
demonstrated efﬁcacy in patients with RA.11 15 16 Therefore, it
was of interest to evaluate these TCZ dose regimens in the early
RA population. Both 8 mg/kg TCZ+placebo and 4 mg/kg TCZ
+MTX achieved DAS28 and ACR efﬁcacy responses consist-
ently at least equal to those observed with placebo+MTX.
These regimens also demonstrated suppression of radiographic
structural joint damage, with 77% (8 mg/kg TCZ+placebo) and
63% (4 mg/kg TCZ+MTX) relative reduction in mTSS to week
52 compared with rates seen in the MTX+placebo group.
Numerically greater inhibition in structural joint damage was
observed with 8 mg/kg TCZ+MTX than with 8 mg/kg TCZ
monotherapy or 4 mg/kg TCZ+MTX. Therefore, although
8 mg/kg TCZ+MTX is the most effective treatment, both 4
mg/kg TCZ+MTX and 8 mg/kg TCZ monotherapy represent
good alternative treatments for subsets of patients, such as those
unable to tolerate MTX or the higher 8 mg/kg dose because of
contraindications or adverse reactions.
Several other biological agents have proven efﬁcacy in the
early RA population. Because of differences in study design,
comparisons across trials are difﬁcult. Nevertheless, TCZ
appears to demonstrate beneﬁts in patients with early RA (in
regard to DAS28 remission, ACR responses and radiographic
endpoints), compared with patients treated with MTX alone,
Table 3 Summary of safety findings (safety population)
Placebo+MTX
n=282
4 mg/kg TCZ+MTX
n=289
8 mg/kg TCZ+MTX
n=290
8 mg/kg TCZ+placebo
n=292
Patients with one or more event, n (%)
Any AEs 235 (83.3) 256 (88.6) 256 (88.3) 250 (85.6)
Infections 136 (48.2) 155 (53.6) 137 (47.2) 138 (47.3)
AEs resulting in premature withdrawal from the study 21 (7.4) 35 (12.1) 59 (20.3) 34 (11.6)
Any SAEs 24 (8.5) 29 (10.0) 31 (10.7) 25 (8.6)
SAEs of special interest
Infections 6 (2.1) 11 (3.8) 10 (3.4) 8 (2.7)
Malignancies 3 (1.1) 4 (1.4) 1 (0.3) 2 (0.7)
Myocardial infarctions 0 3 (1.0) 1 (0.3) 1 (0.3)
Strokes 2 (0.7) 2 (0.7) 0 0
Hypersensitivity reactions 0 1 (0.3) 0 1 (0.3)
Gastrointestinal perforations 1 (0.4) 0 0 0
Hepatic events 0 0 0 0
Deaths, n (%) 2 (0.7) 4 (1.4) 2 (0.7) 1 (0.3)
Clinical laboratory abnormalities
Neutropenia
Grade −3 (<1.0–0.5×109/L) 1 (0.4) 2 (0.7) 10 (3.4) 8 (2.7)
Grade −4 (<0.5×109/L) 0 0 0 1 (0.3)
Thrombocytopenia (based on platelet count)
Grade −3 (<50–25×109/L) 1 (0.4) 1 (0.3) 0 0
Grade −4 (<25×109/L) 1 (0.4) 0 1 (0.3) 0
ALT elevations
Grade 1 (>ULN–2.5× ULN) 120 (42.6) 125 (43.3) 136 (46.9) 115 (39.4)
Grade 2 (>2.5–5× ULN) 21 (7.4) 35 (12.1) 59 (20.3) 19 (6.5)
Grade 3 (>5.0–20× ULN) 3 (1.1) 10 (3.5) 10 (3.4) 5 (1.7)
Grade 4 (>20× ULN) 0 0 0 0
AST elevations
Grade 1 (>ULN–2.5× ULN) 88 (31.2) 95 (32.9) 137 (47.2) 86 (29.5)
Grade 2 (>2.5–5× ULN) 11 (3.9) 12 (4.2) 18 (6.2) 9 (3.1)
Grade 3 (>5.0–20× ULN) 1 (0.4) 1 (0.3) 5 (1.7) 3 (1.0)
Grade 4 (>20× ULN) 0 0 0 0
All values are n (%).
ALT ULN=55 U/L.
AST ULN=40 U/L.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; MTX, methotrexate; SAE, serious adverse event; TCZ, tocilizumab; ULN, upper limit of normal.
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that are generally consistent with those observed in previous
studies of biological therapies in similar populations.1 3 22 26
Although a number of head-to-head comparison studies of dif-
ferent biological agents have recently been published,15 27 these
have generally been performed in patients who have more estab-
lished RA and who have responded inadequately to previous
DMARDs. It would be of interest to conduct such studies in
more treatment-naive patients with early RA.
AEs observed in the TCZ groups were consistent with the
known safety proﬁle of TCZ; no additional safety signals were
observed, and the most frequently reported AE was infection in
all TCZ groups and in the placebo+MTX group. However, a
numerically higher incidence of certain events (infections, malig-
nancies, myocardial infarctions and deaths) was reported in the
4 mg/kg TCZ+MTX group than the other groups. Although
patients in the 4 mg/kg TCZ+MTX group were marginally
older than the other patients, there were no imbalances in any
other baseline demographic or disease characteristics. The sig-
niﬁcance of, and reason for, these small numerical differences
are unclear. Changes in laboratory parameters (eg, increased
hepatic transaminase levels and decreased neutrophil and plate-
let counts) have been reported for TCZ.10–14 Consistent with
the known effects of TCZ and of MTX on transaminase levels,
more patients in the TCZ+MTX groups than in either mono-
therapy group experienced ALT elevations, though AST eleva-
tions were similar between TCZ+MTX and TCZ monotherapy.
Importantly, most elevations occurred at a single time point,
were not sustained and did not result in any clinical sequelae
(no serious hepatic events were reported). Thrombocytopenia
was similar between TCZ+MTX and TCZ monotherapy
groups. Consistent with intravenous TCZ dosing, one hypersen-
sitivity reaction was reported in the 4 mg/kg TCZ+MTX
group and one was reported in the TCZ monotherapy group.
Rates of AEs resulting in premature withdrawal in this study
ranged from 12% in the 4 mg/kg and TCZ monotherapy arms
to 20% in the 8 mg/kg TCZ+MTX arm; these proportions
were higher than in previous studies of TCZ,10–14 which were
conducted in more treatment-experienced populations. The
higher withdrawal rates might have resulted from the protocol-
mandated requirement for withdrawal in response to transamin-
ase elevations (if three consecutive doses of intravenous study
drug were missed because of transaminase elevations, the
patient was withdrawn).
This study had some limitations. The blinded nature pre-
cluded dose modiﬁcation of intravenous TCZ/placebo, MTX
dose was limited to 20 mg/week and laboratory abnormalities
were managed, according to protocol, by interruption or discon-
tinuation of intravenous dosing. These conditions may not
reﬂect actual clinical practice. Furthermore, it is unclear
whether these results are generalisable to patients with early RA
that is less severe.
Overall, the results of this study support the effectiveness and
clinical beneﬁt of TCZ in MTX-naive patients with early pro-
gressive RA. The greatest beneﬁt was afforded by 8 mg/kg TCZ
+MTX; the other TCZ regimens were at least as effective as
MTX in improving signs and symptoms and physical function
and in inhibiting joint damage. These results add to the body of
evidence showing the efﬁcacy of TCZ as therapy for patients
with RA across several populations, including patients who
respond inadequately to DMARDs12–14 16 or to anti-TNF
agents10 and patients who receive TCZ monotherapy because
MTX is contraindicated or cannot be tolerated.11 15 Further
observation of these patients, for up to 2 years of blinded treat-
ment, will investigate the maintenance of clinical (HAQ-DI) and
radiographic outcomes and the long-term safety of TCZ in
patients with early RA and poor prognostic features.
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